Immunogenicity and heterologous protection in mice with a recombinant adenoviral-based vaccine carrying a hepatitis C virus truncated NS3 and core fusion protein.
- Author:
Jie GUAN
;
Yao DENG
;
Hong CHEN
;
Yang YANG
;
Bo WEN
;
Wenjie TAN
- Publication Type:Journal Article
- MeSH:
Adenoviridae;
genetics;
metabolism;
Animals;
CD4-Positive T-Lymphocytes;
immunology;
Cross Protection;
Female;
Genetic Vectors;
biosynthesis;
genetics;
Hepacivirus;
genetics;
immunology;
Hepatitis C;
immunology;
prevention & control;
virology;
Humans;
Interferon-gamma;
immunology;
Mice;
Mice, Inbred BALB C;
Recombinant Proteins;
administration & dosage;
genetics;
immunology;
Viral Core Proteins;
administration & dosage;
genetics;
immunology;
Viral Hepatitis Vaccines;
administration & dosage;
genetics;
immunology;
Viral Nonstructural Proteins;
administration & dosage;
genetics;
immunology
- From:
Chinese Journal of Virology
2015;31(1):7-13
- CountryChina
- Language:Chinese
-
Abstract:
To develop a safe and broad-spectrum effective hepatitis C virus (HCV) T cell vaccine,we constructed the recombinant adenovirus-based vaccine that carried the hepatitis C virus truncated NS3 and core fusion proteins. The expression of the fusion antigen was confirmed by in vitro immunofluorescence and western blotting assays. Our results indicated that this vaccine not only stimulated antigen-specific antibody responses,but also activated strong NS3-specific T cell immune responses. NS3-specific IFN-γ+ and TNF-α+ CD4+ T cell subsets were also detected by a intracellular cytokine secretion assay. In a surrogate challenge assay based on a recombinant heterologous HCV (JFH1,2a) vaccinia virus,the recombinant adenovirus-based vaccine was capable of eliciting effective levels of cross-protection. These findings have im- portant implications for the study of HCV immune protection and the future development of a novel vaccine.
